Latest Breaking News On - Liver institute - Page 1 : comparemela.com

FDA approves Ipsen's Iqirvo 'to address unmet need' in primary biliary cholangitis

The FDA granted accelerated approval to Ipsen Pharma’s Iqirvo 80 mg, a first-in-class oral, once-daily peroxisome proliferator-activated receptor agonist for the treatment of primary biliary cholangitis, according to a company release. Originally given breakthrough therapy designation in 2019, Iqirvo (elafibranor, Ipsen/Genfit), is now indicated as second-line therapy in combination with

FDA Grants Accelerated Approval to Elafibranor (Iqirvo) for PBC

The accelerated approval is based on data from the phase 3 ELATIVE trial demonstrating a reduction in alkaline phosphatase with elafibranor.

Newswire & Press Release / Ipsen's Iqirvo® Receives U.S. FDA Accelerated Approval as A First-in-class PPAR Treatment for Primary Biliary... - Pharma / BioTech / Nutrition - IPSEN Group

Newswire & Press Release / Ipsen's Iqirvo® Receives U.S. FDA Accelerated Approval as A First-in-class PPAR Treatment for Primary Biliary... - Pharma / BioTech / Nutrition - IPSEN Group

Ipsen, Genfit Drug That Missed in MASH Wins FDA Approval in a Much Rarer Liver Disease